Bioxytran (BIXT) Interest Coverage Ratio (2010 - 2026)
Bioxytran (BIXT) posted Interest Coverage Ratio of 54.1 for Q1 2026, down 225.38% sequentially from 16.63 in Q4 2025, and down 227.23% YoY from 42.52 in Q1 2025.
Bioxytran (BIXT) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Bioxytran has reported Interest Coverage Ratio for 17 years, with the latest figure at 54.1 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 227.23% year-over-year to 54.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.48 (down 102.8% YoY) and the FY2025 annual result came in at 0.53, up 26.63% from the prior year.
- Interest Coverage Ratio slipped to 54.1 in Q1 2026 per BIXT's latest filing, from 16.63 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 23.82 in Q4 2022 and troughed at 54.1 in Q1 2026.
- A 5-year average of 12.63 and a median of 13.58 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio surged 4722.24% in 2022, then tumbled 26932.54% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 23.82 in 2022, then sank by 58.95% to 9.78 in 2023, then plunged by 149.7% to 4.86 in 2024, then sank by 242.2% to 16.63 in 2025, then sank by 225.38% to 54.1 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 54.1, 16.63, and 13.58 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -18.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.10 |
| Dec 31, 2025 | -16.63 |
| Sep 30, 2025 | -13.58 |
| Jun 30, 2025 | -7.44 |
| Mar 31, 2025 | -16.53 |
| Dec 31, 2024 | -4.86 |
| Sep 30, 2024 | -19.40 |
| Jun 30, 2024 | -30.88 |
| Mar 31, 2024 | -4.76 |
| Dec 31, 2023 | 9.78 |
| Sep 30, 2023 | -20.24 |
| Jun 30, 2023 | -26.79 |
| Mar 31, 2023 | -8.93 |
| Dec 31, 2022 | 23.82 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | -8.56 |
| Mar 31, 2022 | -15.74 |
| Dec 31, 2021 | -0.52 |
| Sep 30, 2021 | -16.85 |
| Jun 30, 2021 | -12.38 |